Exacerbation of hepatitis E virus infection during anti-TNFα treatment
Standard
Exacerbation of hepatitis E virus infection during anti-TNFα treatment. / Behrendt, Patrick; Lüth, Stefan; Dammermann, Werner; Drave, Svenja; Brown, Richard J P; Todt, Daniel; Schnoor, Ulrike; Steinmann, Eike; Wedemeyer, Heiner; Pischke, Sven; Iking-Konert, Christof.
in: JOINT BONE SPINE, Jahrgang 84, Nr. 2, 03.2017, S. 217-219.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Exacerbation of hepatitis E virus infection during anti-TNFα treatment
AU - Behrendt, Patrick
AU - Lüth, Stefan
AU - Dammermann, Werner
AU - Drave, Svenja
AU - Brown, Richard J P
AU - Todt, Daniel
AU - Schnoor, Ulrike
AU - Steinmann, Eike
AU - Wedemeyer, Heiner
AU - Pischke, Sven
AU - Iking-Konert, Christof
N1 - Copyright © 2016 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.
PY - 2017/3
Y1 - 2017/3
N2 - Chronic hepatitis E virus (HEV) infection may occur in immunocompromised patients. Previous studies report that different immunosuppressive agents interfere with viral replication. However, the role of TNFα in HEV infection is currently unknown. Here, we describe a case of severe exacerbation of a chronic HEV infection in a patient undergoing treatment with a TNFα-inhibitor for psoriatic arthritis despite potent anti-HEV T-cell responses. We used state-of-the-art HEV cell culture methods to test antiviral effects of different drugs and a cytokine release assay to assess HEV specific T cell immunity. In addition standard tools of our diagnostics laboratory were employed. In vitro data confirmed inhibition of HEV replication by TNFα, which could be abolished by addition of TNFα inhibitors. Thus, TNFα may play a critical role in the control of HEV replication. We therefore recommend exclusion of HEV infection prior to initiation of TNFα-inhibitor therapy.
AB - Chronic hepatitis E virus (HEV) infection may occur in immunocompromised patients. Previous studies report that different immunosuppressive agents interfere with viral replication. However, the role of TNFα in HEV infection is currently unknown. Here, we describe a case of severe exacerbation of a chronic HEV infection in a patient undergoing treatment with a TNFα-inhibitor for psoriatic arthritis despite potent anti-HEV T-cell responses. We used state-of-the-art HEV cell culture methods to test antiviral effects of different drugs and a cytokine release assay to assess HEV specific T cell immunity. In addition standard tools of our diagnostics laboratory were employed. In vitro data confirmed inhibition of HEV replication by TNFα, which could be abolished by addition of TNFα inhibitors. Thus, TNFα may play a critical role in the control of HEV replication. We therefore recommend exclusion of HEV infection prior to initiation of TNFα-inhibitor therapy.
U2 - 10.1016/j.jbspin.2016.09.017
DO - 10.1016/j.jbspin.2016.09.017
M3 - SCORING: Journal article
C2 - 27836355
VL - 84
SP - 217
EP - 219
JO - JOINT BONE SPINE
JF - JOINT BONE SPINE
SN - 1297-319X
IS - 2
ER -